drugset / Trial / NCT05654779
CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Terminated
4 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, open-label, single dose-finding and dose-expansion study that evaluates the safety, tolerability, PK, and anti-tumor efficacy of LCAR-AMDR cells in subjects with relapsed/refractory Acute Myeloid Leukemia who received adequate standard therapy.
Timeline
- Start
- 2022-12-12
- Primary completion
- 2023-09-26
- Completion
- 2023-09-26
Outcome
Outcome not reported
Stopped: “Both the sponsors and collaborator are considering terminating the study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCAR-AMDR Cells | Unknown | — | — |